Literature DB >> 18268141

Activatable magnetic resonance imaging agent reports myeloperoxidase activity in healing infarcts and noninvasively detects the antiinflammatory effects of atorvastatin on ischemia-reperfusion injury.

Matthias Nahrendorf1, David Sosnovik, John W Chen, Peter Panizzi, Jose-Luiz Figueiredo, Elena Aikawa, Peter Libby, Filip K Swirski, Ralph Weissleder.   

Abstract

BACKGROUND: Ischemic injury of the myocardium causes timed recruitment of neutrophils and monocytes/macrophages, which produce substantial amounts of local myeloperoxidase (MPO). MPO forms reactive chlorinating species capable of inflicting oxidative stress and altering protein function by covalent modification. We have used a small-molecule, gadolinium-based activatable sensor for magnetic resonance imaging of MPO activity (MPO-Gd). MPO-Gd is first radicalized by MPO and then either spontaneously oligomerizes or binds to matrix proteins, all leading to enhanced spin-lattice relaxivity and delayed washout kinetics. We hypothesized that MPO imaging could be used to measure inflammatory responses after myocardial ischemia locally and noninvasively in a murine model. METHODS AND
RESULTS: We injected 0.3 mmol/kg MPO-Gd (or Gd-DTPA as control) and performed magnetic resonance imaging up to 120 minutes later in mice 2 days after myocardial infarction. The contrast-to-noise ratio (infarct versus septum) after Gd-DTPA injection peaked at 10 minutes and returned to preinjection values at 60 minutes. After injection of MPO-Gd, the contrast-to-noise ratio peaked later and was higher than Gd-DTPA (40.8+/-10.4 versus 10.5+/-0.2; P<0.05). MPO imaging was validated by magnetic resonance imaging of MPO-/- mice and correlated well with immunoreactive staining (r2=0.92, P<0.05), tissue activity by guaiacol assay (r2=0.65, P<0.001), and immunoblotting. In time course imaging, activity peaked 2 days after coronary ligation. Flow cytometry of digested infarcts detected MPO in neutrophils and monocytes/macrophages. Furthermore, serial MPO imaging accurately tracked the antiinflammatory effects of atorvastatin therapy after ischemia-reperfusion injury.
CONCLUSIONS: MPO-Gd enables in vivo assessment of MPO activity in injured myocardium. This approach allows noninvasive evaluation of the inflammatory response to ischemia and has the potential to guide the development of novel cardioprotective therapies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18268141      PMCID: PMC2673051          DOI: 10.1161/CIRCULATIONAHA.107.756510

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  36 in total

1.  HMG-CoA reductase inhibition protects the diabetic myocardium from ischemia-reperfusion injury.

Authors:  D J Lefer; R Scalia; S P Jones; B R Sharp; M R Hoffmeyer; A R Farvid; M F Gibson; A M Lefer
Journal:  FASEB J       Date:  2001-06       Impact factor: 5.191

2.  Neutrophilia and congestive heart failure after acute myocardial infarction.

Authors:  L Kyne; J M Hausdorff; E Knight; L Dukas; G Azhar; J Y Wei
Journal:  Am Heart J       Date:  2000-01       Impact factor: 4.749

Review 3.  The inflammatory response in myocardial infarction.

Authors:  Nikolaos G Frangogiannis; C Wayne Smith; Mark L Entman
Journal:  Cardiovasc Res       Date:  2002-01       Impact factor: 10.787

4.  Pretreatment with simvastatin attenuates myocardial dysfunction after ischemia and chronic reperfusion.

Authors:  S P Jones; S D Trocha; D J Lefer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-12       Impact factor: 8.311

5.  Prognostic significance of peripheral monocytosis after reperfused acute myocardial infarction:a possible role for left ventricular remodeling.

Authors:  Yuichiro Maekawa; Toshihisa Anzai; Tsutomu Yoshikawa; Yasushi Asakura; Toshiyuki Takahashi; Shiro Ishikawa; Hideo Mitamura; Satoshi Ogawa
Journal:  J Am Coll Cardiol       Date:  2002-01-16       Impact factor: 24.094

Review 6.  Dynamics of cardiac wound healing following myocardial infarction: observations in genetically altered mice.

Authors:  W M Blankesteijn; E Creemers; E Lutgens; J P Cleutjens; M J Daemen; J F Smits
Journal:  Acta Physiol Scand       Date:  2001-09

7.  Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis.

Authors:  Matthias Nahrendorf; Farouc A Jaffer; Kimberly A Kelly; David E Sosnovik; Elena Aikawa; Peter Libby; Ralph Weissleder
Journal:  Circulation       Date:  2006-09-25       Impact factor: 29.690

8.  Acute reduction of myocardial infarct size by a hydroxymethyl glutaryl coenzyme A reductase inhibitor is mediated by endothelial nitric oxide synthase.

Authors:  Sebastian Wolfrum; Michael Grimm; Marc Heidbreder; Andreas Dendorfer; Hugo A Katus; James K Liao; Gert Richardt
Journal:  J Cardiovasc Pharmacol       Date:  2003-03       Impact factor: 3.105

9.  Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol.

Authors:  Galina K Sukhova; J Koudy Williams; Peter Libby
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-09-01       Impact factor: 8.311

10.  Human neutrophils use the myeloperoxidase-hydrogen peroxide-chloride system to chlorinate but not nitrate bacterial proteins during phagocytosis.

Authors:  Henry Rosen; Jan R Crowley; Jay W Heinecke
Journal:  J Biol Chem       Date:  2002-06-11       Impact factor: 5.157

View more
  79 in total

Review 1.  Targeted probes for cardiovascular MRI.

Authors:  Ritika Uppal; Peter Caravan
Journal:  Future Med Chem       Date:  2010-03       Impact factor: 3.808

Review 2.  Molecular body imaging: MR imaging, CT, and US. part I. principles.

Authors:  Moritz F Kircher; Jürgen K Willmann
Journal:  Radiology       Date:  2012-06       Impact factor: 11.105

Review 3.  CMR for characterization of the myocardium in acute coronary syndromes.

Authors:  Erica Dall'Armellina; Theodoros D Karamitsos; Stefan Neubauer; Robin P Choudhury
Journal:  Nat Rev Cardiol       Date:  2010-09-21       Impact factor: 32.419

Review 4.  Molecular imaging of atherosclerosis for improving diagnostic and therapeutic development.

Authors:  Thibaut Quillard; Peter Libby
Journal:  Circ Res       Date:  2012-07-06       Impact factor: 17.367

Review 5.  Molecular imaging of fibrosis: recent advances and future directions.

Authors:  Sydney B Montesi; Pauline Désogère; Bryan C Fuchs; Peter Caravan
Journal:  J Clin Invest       Date:  2019-01-02       Impact factor: 14.808

6.  Multiple sclerosis: myeloperoxidase immunoradiology improves detection of acute and chronic disease in experimental model.

Authors:  Benjamin Pulli; Lionel Bure; Gregory R Wojtkiewicz; Yoshiko Iwamoto; Muhammad Ali; Dan Li; Stefan Schob; Kevin Li-Chun Hsieh; Andreas H Jacobs; John W Chen
Journal:  Radiology       Date:  2014-12-10       Impact factor: 11.105

Review 7.  Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers.

Authors:  Jessica Wahsner; Eric M Gale; Aurora Rodríguez-Rodríguez; Peter Caravan
Journal:  Chem Rev       Date:  2018-10-16       Impact factor: 60.622

8.  Activatable magnetic resonance imaging agents for myeloperoxidase sensing: mechanism of activation, stability, and toxicity.

Authors:  Elisenda Rodríguez; Mark Nilges; Ralph Weissleder; John W Chen
Journal:  J Am Chem Soc       Date:  2010-01-13       Impact factor: 15.419

9.  18F-4V for PET-CT imaging of VCAM-1 expression in atherosclerosis.

Authors:  Matthias Nahrendorf; Edmund Keliher; Peter Panizzi; Hanwen Zhang; Sheena Hembrador; Jose-Luiz Figueiredo; Elena Aikawa; Kimberly Kelly; Peter Libby; Ralph Weissleder
Journal:  JACC Cardiovasc Imaging       Date:  2009-10

10.  Monocyte-directed RNAi targeting CCR2 improves infarct healing in atherosclerosis-prone mice.

Authors:  Maulik D Majmudar; Edmund J Keliher; Timo Heidt; Florian Leuschner; Jessica Truelove; Brena F Sena; Rostic Gorbatov; Yoshiko Iwamoto; Partha Dutta; Gregory Wojtkiewicz; Gabriel Courties; Matt Sebas; Anna Borodovsky; Kevin Fitzgerald; Marc W Nolte; Gerhard Dickneite; John W Chen; Daniel G Anderson; Filip K Swirski; Ralph Weissleder; Matthias Nahrendorf
Journal:  Circulation       Date:  2013-04-24       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.